ADIUVO-2 is a randomized registry trial of adjuvant mitotane versus mitotane with cisplatin/etoposide after primary surgical resection of localized ACC with high risk of recurrence (stage I–III, and Ki-67 >10%). The gene discussed is MKI67; the disease is adrenal cortex carcinoma.